BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 2397748)

  • 1. In vitro cytotoxicity of VP-16-213 and nitrogen mustard: agonistic on tumor cells but not on normal human bone marrow progenitors.
    Lemoli RM; Gulati SC
    Exp Hematol; 1990 Oct; 18(9):1008-12. PubMed ID: 2397748
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Photoradiation methods for purging autologous bone marrow grafts.
    Gulati S; Atzpodien J; Lemoli RM; Shimazaki C; Clarkson B
    Prog Clin Biol Res; 1990; 333():87-102. PubMed ID: 2137934
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential sensitivity of adherent CFU-blast, CFU-mix, BFU-E, and CFU-GM to mafosfamide: implications for adjusted dose purging in autologous bone marrow transplantation.
    Carlo-Stella C; Mangoni L; Almici C; Garau D; Craviotto L; Piovani G; Caramatti C; Rizzoli V
    Exp Hematol; 1992 Mar; 20(3):328-33. PubMed ID: 1568448
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proliferative response of human marrow myeloid progenitor cells to in vivo treatment with granulocyte colony-stimulating factor alone and in combination with interleukin-3 after autologous bone marrow transplantation.
    Lemoli RM; Fortuna A; Fogli M; Gherlinzoni F; Rosti G; Catani L; Gozzetti A; Miggiano MC; Tura S
    Exp Hematol; 1995 Dec; 23(14):1520-6. PubMed ID: 8542941
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TGF-beta 3 protects normal human hematopoietic progenitor cells treated with 4-hydroperoxycyclophosphamide in vitro.
    Lemoli RM; Strife A; Clarkson BD; Haley JD; Gulati SC
    Exp Hematol; 1992 Dec; 20(11):1252-6. PubMed ID: 1493854
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elimination of clonogenic tumor cells from bone marrow using methylprednisolone (MP) and etoposide VP16: an in vitro pharmacologic study.
    Miller G; Brashear T; Stone M; Fay J
    Int J Cell Cloning; 1991 Sep; 9(5):503-10. PubMed ID: 1955738
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic effect of 4-hydroperoxycyclophosphamide and etoposide on a human promyelocytic leukemia cell line (HL-60) demonstrated by computer analysis.
    Chang TT; Gulati SC; Chou TC; Vega R; Gandola L; Ibrahim SM; Yopp J; Colvin M; Clarkson BD
    Cancer Res; 1985 Jun; 45(6):2434-9. PubMed ID: 3857119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of etoposide in combination with cyclosporin for purging multidrug-resistant leukemic cells from bone marrow in a mouse model.
    Kühl JS; Sikic BI; Blume KG; Chao NJ
    Exp Hematol; 1992 Oct; 20(9):1048-54. PubMed ID: 1468539
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological purging of minimal residual disease from peripheral blood stem cell collections of acute myeloblastic leukemia patients: preclinical studies.
    Motta MR; Mangianti S; Rizzi S; Ratta M; Campanini E; Fortuna A; Fogli M; Tura S; Lemoli RM
    Exp Hematol; 1997 Nov; 25(12):1261-9. PubMed ID: 9357970
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of recombinant human stem cell factor on mafosfamide-treated bone marrow clonogenic cells.
    Carlo-Stella C; Mangoni L; Almici C; Caramatti C; Rizzoli V
    Stem Cells; 1993 Jul; 11 Suppl 2():170-4. PubMed ID: 7691323
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical studies of the combination of mafosfamide (Asta-Z 7654) and etoposide (VP-16-213) for purging leukemic autologous marrow.
    Tamayo E; Hervé P
    Exp Hematol; 1988 Feb; 16(2):97-101. PubMed ID: 3276544
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of a combined treatment with ASTA-Z 7654 and VP16-213 in vitro in eradicating clonogenic tumor cells from human bone marrow.
    De Fabritiis P; Pulsoni A; Sandrelli A; Simone F; Amadori S; Meloni G; Mandelli F
    Bone Marrow Transplant; 1987 Oct; 2(3):287-98. PubMed ID: 3502785
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential cytotoxicity of an ether lipid on lymphoma and bone marrow cells and its role in purging malignant lymphoid cells from remission bone marrow contaminated with tumor cells.
    Dietzfelbinger HF; Lang A; Oberberg D; Rastetter JW; Berdel WE
    Exp Hematol; 1992 Feb; 20(2):178-83. PubMed ID: 1544386
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of recombinant human tumor necrosis factor on highly enriched hematopoietic progenitor cell populations from normal human bone marrow and peripheral blood and bone marrow from patients with chronic myeloid leukemia.
    Wisniewski D; Strife A; Atzpodien J; Clarkson BD
    Cancer Res; 1987 Sep; 47(18):4788-94. PubMed ID: 3040231
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of stem cell factor (c-kit ligand), granulocyte-macrophage colony stimulating factor and interleukin 3 on hematopoietic progenitors in human long-term bone marrow cultures.
    Lemoli RM; Gulati SC
    Stem Cells; 1993 Sep; 11(5):435-44. PubMed ID: 7694721
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the cytotoxic effects of merocyanine-540 on leukemic cells and normal human bone marrow.
    Atzpodien J; Gulati SC; Clarkson BD
    Cancer Res; 1986 Oct; 46(10):4892-5. PubMed ID: 3756850
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of in vivo treatment with PIXY321 (GM-CSF/IL-3 fusion protein) on proliferation kinetics of bone marrow and blood myeloid progenitor cells in patients with sarcoma.
    Broxmeyer HE; Benninger L; Cooper S; Hague N; Benjamin RS; Vadhan-Raj S
    Exp Hematol; 1995 Apr; 23(4):335-40. PubMed ID: 7895781
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of in vitro inhibition of etoposide (VP16) on leukemic and normal myeloid, erythroid clonogenic cells.
    Lagneaux L; Marie JP; Delforge A; Socquet M; Thevenin D; Zittoun R; Stryckmans P
    Exp Hematol; 1989 Aug; 17(7):843-6. PubMed ID: 2753092
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The suppressive influences of human tumor necrosis factors on bone marrow hematopoietic progenitor cells from normal donors and patients with leukemia: synergism of tumor necrosis factor and interferon-gamma.
    Broxmeyer HE; Williams DE; Lu L; Cooper S; Anderson SL; Beyer GS; Hoffman R; Rubin BY
    J Immunol; 1986 Jun; 136(12):4487-95. PubMed ID: 3086433
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of doxorubicin in combination with mafosfamide for in vitro elimination of myeloid and lymphoid tumor cells from human bone marrow.
    Domenech J; Georget MT; Gihana E; Colombat P; Brémond JL; Chassaigne M; Lamagnère JP; Binet C
    Bone Marrow Transplant; 1992 Feb; 9(2):101-6. PubMed ID: 1571708
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.